Skip to main content

Table 1 Characteristics of the 100 patients included in the cross-sectional analysis and of 62 patients included in the progression analyses, stratified by pre-transplant treatment modality

From: Pretransplant dialysis treatment and vascular calcification of the iliac artery and abdominal aorta in kidney transplant patients

 

Cross-sectional cohort

Longitudinal cohort

HD (n = 61)

PD (n = 22)

PEKT (n = 17)

HD (n = 39)

PD (n = 16)

PEKT (n = 7)

Age, years

47.9 ± 12.5

47.3 ± 14.9

44.2 ± 13.2

48.5 ± 10.7

46.3 ± 14.6

36.3 ± 11.5 a

Male, n (%)

39 (64)

16 (73)

14 (82)

24 (62)

13 (81)

5 (71)

Diabetes mellitus, n (%)

12 (20)

3 (14)

3 (18)

8 (21)

1 (6)

1 (14)

Dialysis vintage, months

91 [11.5, 180.5]

21.5 [11.5, 35.3] a

–

91 [12, 179]

19.5 [7, 32.5] a

–

History of CVD, n (%)

8 (13)

1 (5)

0 (0)

6 (15)

0 (0)

0 (0)

Body mass index

21.3 ± 3.3

22.3 ± 3.3

21.6 ± 4.4

21.7 ± 3.6

21.8 ± 2.5

20.0 ± 4.9

Systolic BP, mmHg

130 ± 16

125 ± 13

129 ± 10

130 ± 16

123 ± 12

129 ± 14

Diastolic BP, mmHg

76 ± 10

76 ± 10

83 ± 10 a

76 ± 10

76 ± 11

79 ± 13

ABO incompatible, n (%)

19 (31)

5 (23)

6 (35)

15 (38)

5 (31)

1 (14)

Donor-specific antigen, n (%)

13 (21)

1 (5)

5 (29)

7 (18)

1 (6)

1 (14)

HLA mismatch count (A, B, DR)

3.1 ± 1.4

3.6 ± 1.4

3.1 ± 1.9

3.3 ± 1.5

3.8 ± 1.5

3.0 ± 2.2

Donor characteristics

Living donor, n (%)

43 (70)

20 (91) a

17 (100) a

30 (77)

15 (94)

7 (100)

Male, n (%)

32 (52)

7 (32)

7 (41)

25 (64)

6 (38)

4 (57)

Age, years

52.3 ± 13.2

56.9 ± 10.1

56.5 ± 8.0

54.0 ± 12.5

56.3 ± 11.1

55.9 ± 5.6

Body weight, kg

58.2 ± 9.2

55.2 ± 10.1

55.3 ± 9.3

59.8 ± 9.4

55.6 ± 11.4

57.9 ± 10.2

Medication before transplantation, n (%)

Calcium-based phosphate binders

39 (64)

13 (59)

2 (12)

26 (67)

9 (56)

1 (14)

Calcium-free phosphate binders

29 (48)

12 (55)

1 (6)

16 (41)

7 (44)

1 (14)

Vitamin D

48 (79)

8 (36)

2 (12)

30 (77)

6 (38)

1 (14)

Calcimimetics

18 (30)

2 (9)

0 (0)

11 (28)

2 (13)

0 (0)

HbA1c, %

5.5 ± 0.8

5.3 ± 0.3

5.3 ± 0.5

5.6 ± 0.8

5.3 ± 0.3

5.5 ± 0.4

Whole PTH, pg/mL

89.2 [34.8, 162.0]

117.0 [78.4, 145.3]

204.0 [176.5, 262.0] a

74.9 [29.3, 189.0]

123.6 [80.4, 150.5]

215.0 [202.0, 238.0]

Calcium, mg/dL

9.5 ± 0.9

9.1 ± 0.7

8.5 ± 1.3 a

9.4 ± 1.0

9.1 ± 0.7

8.2 ± 1.7 a

Phosphate, mg/dL

4.9 ± 1.2

5.6 ± 1.2

5.3 ± 1.6 a, b

4.9 ± 1.3

5.5 ± 1.3

5.4 ± 2.1

LDL cholesterol, mg/dL

91.2 ± 31.9

91.9 ± 26.5

84.2 ± 33.9

88.3 ± 30.4

89.3 ± 25.9

78.5 ± 31.9

Nadir creatinine, mg/dL

1.16 ± 0.45

1.05 ± 0.19

1.05 ± 0.23

1.13 ± 0.41

1.05 ± 0.17

0.98 ± 0.22

Laboratory data at 3 months after transplantation

Calcium, mg/dL

10.1 ± 1.1

10.1 ± 0.6

9.3 ± 0.3 a, b

10.1 ± 1.1

10.1 ± 0.7

9.3 ± 0.4

Phosphate, mg/dL

2.8 ± 0.8

2.7 ± 0.6

2.8 ± 0.5

2.9 ± 0.9

2.6 ± 0.6

2.7 ± 0.5

LDL cholesterol, mg/dL

116.3 ± 30.3

111.8 ± 27.0

106.2 ± 28.1

116.0 ± 28.6

115.5 ± 26.1

87.1 ± 17.5 a

  1. Data are expressed as the mean ± standard deviation, median [interquartile range], or number of patients (%). HD hemodialysis, PD peritoneal dialysis, PEKT pre-emptive kidney transplantation, CVD cardiovascular diseases, BP blood pressure, PTH parathyroid hormone, LDL low-density lipoprotein
  2. ap < 0.05 compared to HD patients
  3. bp < 0.05 compared to PD patients